CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

James McArthur

Chief Executive Officer, PepGen

Search every verified James McArthur interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a July 2022 interview on The Business of Biotech podcast, James McArthur, President and CEO of PepGen, discussed the company's work developing peptide-conjugated oligonucleotide candidates for degenerative neuromuscular diseases, including Duchenne muscular dystrophy (DMD). He stated that therapeutic oligonucleotides have shown potential for effects like exon skipping in neuromuscular diseases, but noted the challenge of getting them into cells, which he said was the focus of the company's academic founders. McArthur also provided an update on PepGen's clinical progress, mentioning a healthy volunteer study for one program and plans for readouts in the first half of 2024 for two lead programs. McArthur said the company's capital, including a $112 million Series B closed in August 2021, would fund operations well into 2025, beyond the anticipated readout dates. He described the company's approach as capital efficient, stating that PepGen would not grow its team dramatically and would remain between 40 and 50 people, a size he said was appropriate given the difficult market conditions for companies.

Recent appearances

  • PepGen - Meet the DM Drug Developers 2025

    November 13, 2025 · 📺 Myotonic Dystrophy Foundation

    Originally presented on November 7th, 2025. PepGen presents an update on their DM program. Learn more the FREEDOM2-DM1 study at: https://www.freedom2-dm1.com/ Learn more about PepGen at: https://www.pepgen.com/ ========================== Presenters include: James McArthur, PhD,President and Chief Executive Officer at PepGen Jane Larkindale, D.Phil,Vice President of Clinical Science at PepGen Sophia Roe,Patient Advocacy Associate at PepGen Johanna Hamel, MDAssociate Professor of Neurology, Pathology, & Laboratory Medicine at the University of Rochester ========================== Each…

    Watch on YouTube ↗

  • Oligonucleotide Opportunities in DMD with PepGen's James McArthur, Ph.D.

    July 25, 2022 · 📺 Life Science Connect

    Among the more prevalent genetic conditions, Duchenne muscular dystrophy affects an estimated one in 3,500 male births worldwide. It's caused by mutations of the DMD gene, which regulates the production of a protein called dystrophin. Approved DMD treatments haven't demonstrated strong clinical outcomes, but James McArthur, Ph.D. and his team at PepGen are seeking to change that with a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates derived from the company's Enhanced Delivery Oligonucleotide platform. The Business of Biotech caught up with Dr. McArthur at PepGen's…

    Watch on YouTube ↗

  • PepGen, Inc. Unlocking the Potential of Exon Skipping Therapeutics

    May 23, 2021 · 📺 CureDuchenneMD

    PepGen presents an overview of its enhanced delivery oligonucleotide platform and how this innovative platform technology is being applied to create a transformative exon skipping therapy. James McArthur, CEO of PepGen discusses the technology with the community and plans for next stages of development. Follow us on Facebook:   / cureduchenne   Follow us on Twitter:   / cureduchenne   Follow us on Instagram:   / cureduchenne  

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →